These findings uncover a non-canonical mechanism of action for GLP-1 analogs, highlighting a specific microbiota-endocannabinoid metabolic pathway as a potential therapeutic target for depression.
& Akerstrom, V
The FDA approved the GLP-1 drug Ozempic to reduce the risk of chronic kidney disease (CKD) progression among those with type 2 diabetes and CKD in 2025
As the use of these medications continues to grow, our findings provide important reassurance to patients and clinicians alike that these treatments can support both body and mind, investigator Toby Pillinger, PhD, clinical lecturer, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, England, told Medscape Medical News
Compliance improves when veterinarians explain medications, simplify the treatment regime, and demonstrate how to administer the medication (3)
10.1016/j.cmet.2010.04.014 332